258 related articles for article (PubMed ID: 21664089)
1. Investigation and structural elucidation of a process related impurity in candesartan cilexetil by LC/ESI-ITMS and NMR.
Raman B; Sharma BA; Mahale G; Singh D; Kumar A
J Pharm Biomed Anal; 2011 Sep; 56(2):256-63. PubMed ID: 21664089
[TBL] [Abstract][Full Text] [Related]
2. Identification and characterization of potential impurities of valsartan, AT1 receptor antagonist.
Sampath A; Reddy AR; Yakambaram B; Thirupathi A; Prabhakar M; Reddy PP; Reddy VP
J Pharm Biomed Anal; 2009 Oct; 50(3):405-12. PubMed ID: 19560892
[TBL] [Abstract][Full Text] [Related]
3. LC and LC-MS/TOF studies on stress degradation behaviour of candesartan cilexetil.
Mehta S; Shah RP; Priyadarshi R; Singh S
J Pharm Biomed Anal; 2010 Jul; 52(3):345-54. PubMed ID: 19505786
[TBL] [Abstract][Full Text] [Related]
4. Identification and structural elucidation of an unknown impurity in carbamazepine active pharmaceutical ingredient by liquid chromatography-tandem mass spectrometry and semi-preparative chromatographic isolation.
Thomas S; Mathela CS; Agarwal A; Paul SK
J Pharm Biomed Anal; 2011 Sep; 56(2):423-8. PubMed ID: 21676571
[TBL] [Abstract][Full Text] [Related]
5. Investigation of amodiaquine bulk drug impurities by liquid chromatography/ion trap mass spectrometry.
Dongre VG; Karmuse PP; Ghugare PD; Kanojiya SK; Rawal S
Rapid Commun Mass Spectrom; 2008 Jul; 22(14):2227-33. PubMed ID: 18543378
[TBL] [Abstract][Full Text] [Related]
6. Identification, characterization and quantification of a new impurity in deferasirox active pharmaceutical ingredient by LC-ESI-QT/MS/MS.
Thomas S; Chandra Joshi S; Vir D; Agarwal A; Rao RD; Sridhar I; Xavier CM; Mathela CS
J Pharm Biomed Anal; 2012 Apr; 63():112-9. PubMed ID: 22361658
[TBL] [Abstract][Full Text] [Related]
7. Characterization of conjugated metabolites of a new angiotensin II receptor antagonist, candesartan cilexetil, in rats by liquid chromatography/electrospray tandem mass spectrometry following chemical derivatization.
Kondo T; Yoshida K; Yoshimura Y; Motohashi M; Tanayama S
J Mass Spectrom; 1996 Aug; 31(8):873-8. PubMed ID: 8799313
[TBL] [Abstract][Full Text] [Related]
8. Highly efficient, selective, sensitive and stability indicating RP-HPLC-UV method for the quantitative determination of potential impurities and characterization of four novel impurities in eslicarbazepine acetate active pharmaceutical ingredient by LC/ESI-IT/MS/MS.
Thomas S; Bharti A; Maddhesia PK; Shandilya S; Agarwal A; Dharamvir ; Biswas S; Bhansal V; Gupta AK; Tewari PK; Mathela CS
J Pharm Biomed Anal; 2012 Mar; 61():165-75. PubMed ID: 22178334
[TBL] [Abstract][Full Text] [Related]
9. Structural elucidation of impurities in 5-n-butyl-4-{4-[2-(1H-tetrazole-5-yl)-1H-pyrrol-1-yl]phenylmethyl}-2,4-dihydro-2-(2,6-dichlorophenyl)-3H-1,2,4-triazol-3-one (Ib), a novel nonpeptide angiotensin AT1 receptor antagonist.
Gao T; Liu Y; Ji Y; Wu X; Xu J
J Pharm Biomed Anal; 2012 Jul; 66():381-6. PubMed ID: 22516679
[TBL] [Abstract][Full Text] [Related]
10. Identification and characterization of process related impurities in chloroquine and hydroxychloroquine by LC/IT/MS, LC/TOF/MS and NMR.
Dongre VG; Ghugare PD; Karmuse P; Singh D; Jadhav A; Kumar A
J Pharm Biomed Anal; 2009 May; 49(4):873-9. PubMed ID: 19201565
[TBL] [Abstract][Full Text] [Related]
11. Identification, isolation, synthesis and characterization of impurities of quetiapine fumarate.
Bharathi Ch; Prabahar KJ; Prasad ChS; Srinivasa Rao M; Trinadhachary GN; Handa VK; Dandala R; Naidu A
Pharmazie; 2008 Jan; 63(1):14-9. PubMed ID: 18271296
[TBL] [Abstract][Full Text] [Related]
12. Structural studies of racecadotril and its process impurities by NMR and mass spectroscopy.
Reddy KM; Babu JM; Sudhakar P; Sharma MS; Reddy GS; Vyas K
Pharmazie; 2006 Dec; 61(12):994-8. PubMed ID: 17283655
[TBL] [Abstract][Full Text] [Related]
13. Structural identification and characterization of impurities in ceftizoxime sodium.
Bharathi Ch; Prasad ChS; Bharathi DV; Shankar R; Rao VJ; Dandala R; Naidu A
J Pharm Biomed Anal; 2007 Jan; 43(2):733-40. PubMed ID: 16950586
[TBL] [Abstract][Full Text] [Related]
14. Isolation and structural identification of an impurity in fluconazole bulk drug substance.
Dongre VG; Ghugare PD; Karmuse PP; Soudagar SR; Panda N; Kumar A
J Pharm Biomed Anal; 2007 Nov; 45(3):422-9. PubMed ID: 17706390
[TBL] [Abstract][Full Text] [Related]
15. Separation and characterization of synthetic impurities of triclabendazole by reversed-phase high-performance liquid chromatography/electrospray ionization mass spectrometry.
Zhou H; Tai Y; Sun C; Pan Y
J Pharm Biomed Anal; 2005 Feb; 37(1):97-107. PubMed ID: 15664748
[TBL] [Abstract][Full Text] [Related]
16. Structural identification and characterization of potential impurities of pantoprazole sodium.
Reddy GM; Bhaskar BV; Reddy PP; Ashok S; Sudhakar P; Babu JM; Vyas K; Mukkanti K
J Pharm Biomed Anal; 2007 Oct; 45(2):201-10. PubMed ID: 17629653
[TBL] [Abstract][Full Text] [Related]
17. Characterization of impurities in semi-synthetic vinorelbine bitartrate by HPLC-MS with mass spectrometric shift technique.
Cao X; Tai Y; Sun C; Wang K; Pan Y
J Pharm Biomed Anal; 2005 Sep; 39(1-2):39-45. PubMed ID: 16085133
[TBL] [Abstract][Full Text] [Related]
18. Identification, isolation and characterization of impurities of clindamycin palmitate hydrochloride.
Bharathi Ch; Jayaram P; Sunder Raj J; Saravana Kumar M; Bhargavi V; Handa VK; Dandala R; Naidu A
J Pharm Biomed Anal; 2008 Dec; 48(4):1211-8. PubMed ID: 18947955
[TBL] [Abstract][Full Text] [Related]
19. Synthesis of telmisartan impurity B.
Zhao L; Xia H; Wang ZC
Pharmazie; 2013 Jun; 68(6):392-5. PubMed ID: 23875243
[TBL] [Abstract][Full Text] [Related]
20. Candesartan cilexetil.
Ardiana F; Lestari ML; Indrayanto G
Profiles Drug Subst Excip Relat Methodol; 2012; 37():79-112. PubMed ID: 22469317
[No Abstract] [Full Text] [Related]
[Next] [New Search]
